Firma 4SC, Autor bei PR-Web

4SC provides Q3 highlights and financial forecast

Posted on 19. October 2021 by Firma 4SC Posted in General Tagged 4sc, clinical, domatinostat, esmo, forecast, immunic, mcc, merklin, patients, report, resmain, statements, thousand, turandot, with

4SC AG (4SC, FSE Prime Standard: VSC) today provided a business update for the three months ended 30 September 2021, as well as its current outlook. The full report is available for download on 4SC’s website (https://www.4sc.com/investors/investor-information/financial-reports/). Key highlights of […]

4SC AG: 4SC – Clinical Study Presentations at the ESMO congress 2021

Posted on 16. September 2021 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, cancer, cell, domatinostat, gamma, hdac, ifn, mcc, merck, merklin, patients, SEP, statements, with

. – MERKLIN1 study progress update – EMERGE phase IIa clinical data presentation – DONIMI phase Ib clinical data presentation 4SC AG (4SC, FSE Prime Standard: VSC) today announced that presentations on clinical studies combining domatinostat and immune checkpoint inhibitor therapy will […]

4SC – Clinical Study Presentations at the 31. German Conference of Skin Cancer (31. Hautkrebskongress)

Posted on 8. September 2021 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, axitinib, bavencio, cancer, domatinostat, hepatitis, hypertension, hypothyroidism, merck, merklin, patients, pediatric, statements, with

* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with treatment-naïve metastatic Merkel cell carcinoma – […]

4SC AG: 6 upcoming conferences

Posted on 24. August 2021 by Firma 4SC Posted in Events Tagged 4sc, any, cancer, conference, esmo, financial, hybrid, immunotherapy, lymphoma, press, risks, statements, symposium, virtual, wwwado

4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation in upcoming financial and scientific conferences. 4SC’s management and/or scientists will be available for personal contact at these events. 31. Dt. Hautkrebskongress / ADO-Jahrestagung (https://www.ado-kongress.de/)08.09.-11.09.21 Hybrid Venue (Virtual) H.C. […]

4SC provides Q2 2021 and H1 2021 update

Posted on 10. August 2021 by Firma 4SC Posted in General Tagged 4sc, asco, cancer, cell, domatinostat, esmo, forecast, immunic, merklin, patients, resmain, resminostat, statements, urothelial, with

4SC AG (4SC, FSE Prime Standard: VSC) today published its Half-Year Report 2021, presenting all material developments up to 30 June 2021 and the Company’s current outlook. The full communication is available for download on 4SC’s website (http://www.4sc.com/investors/investor-information/financial-reports/). Jason Loveridge, […]

4SC AG: 4SC announces implementation of 5:1 reverse share split as previously announced

Posted on 13. July 2021 by Firma 4SC Posted in General Tagged 4sc, 5c4, any, clinical, company, de000a3e5c40, new, par, prior, risks, securities, shareholders, statements, trading, with

. – Intention to conduct a reverse share split announced on 6 May 2021 – Stock quotation to change on 19 July 2021 – 4SC shares allocated a new ISIN (DE000A3E5C40) and WKN (A3E 5C4) 4SC AG (4SC, FSE Prime Standard: VSC) […]

4SC AG: 4SC to present results from the SENSITIZE study at the (virtual) 2021 ASCO Annual Meeting

Posted on 7. June 20217. June 2021 by Firma 4SC Posted in General Tagged 4sc, avelumab, braf, cancer, cell, domatinostat, dosing, hdac, heidelberg, mcc, merck, merklin, patients, statements, with

Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, Germany, Department of Dermatology and National Center for Tumor Diseases, presents a poster and associated slide presentation at the virtual 2021 ASCO Annual Meeting […]

4SC AG plans reduction of share capital through a reverse split of shares

Posted on 7. May 2021 by Firma 4SC Posted in General Tagged 4sc, any, board, capital, companys, expected, may, measures, new, press, release, risks, statements, supervisory, with

The Management Board and Supervisory Board of4SC AG (FSE Prime Standard: VSC) today decided to propose to the Annual General Meeting to be held on 24 June 2021 the reduction of the Company’s share capital through a reverse split of […]

4SC AG: 4SC provides Q1 2021 update

Posted on 20. April 2021 by Firma 4SC Posted in General Tagged 4sc, board, clinical, domatinostat, financial, forecast, immunic, patients, resmain, resminostat, risks, royalty, statements, thousand, with

4SC AG (4SC, FSE Prime Standard: VSC) today published the Q1 Announcement 2021, presenting all material developments up to 31 March 2021 and the Company’s current outlook. The full communication is available for download on 4SC’s website (http://www.4sc.com/investors/investor-information/financial-reports/). Jason Loveridge, […]

4SC to present at the virtual 10th World Congress of Melanoma and 17th EADO Congress

Posted on 15. April 2021 by Firma 4SC Posted in Research / Development Tagged 4sc, avelumab, cancer, ctcl, domatinostat, honsha, merck, merklin, patients, resmain, resminostat, statements, syndrome, with, yakult

4SC AG (4SC, FSE Prime Standard: VSC) will attend and present at the virtual 10th World Congress of Melanoma and 17th EADO Congress, from the 15-17 April 2021. A summary of the key clinical trial updates are listed below: * […]